Quick Answer
BRAINSTORM CELL THERAPEUTICS INC. reported Research And Development Expense of $4.18 million for the year ending 2025.
- BRAINSTORM CELL THERAPEUTICS INC. showed a decrease of -10.2% in Research And Development Expense from 2024 to 2025.
- This data is from BRAINSTORM CELL THERAPEUTICS INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), BRAINSTORM CELL THERAPEUTICS INC.'s Research And Development Expense has grown by 299.5%.
- Historical annual values: Fiscal year 2025: $4.18 million | Fiscal year 2024: $4.65 million | Fiscal year 2023: $10.75 million | Fiscal year 2022: $13.96 million | Fiscal year 2021: $15.24 million | Fiscal year 2020: $22.33 million | Fiscal year 2019: $17.20 million | Fiscal year 2018: $8.29 million | Fiscal year 2017: $977.0 thousand | Fiscal year 2016: $2.25 million | Fiscal year 2015: $4.95 million | Fiscal year 2014: $4.77 million | Fiscal year 2013: $2.92 million | Fiscal year 2012: $1.77 million | Fiscal year 2011: $1.69 million | Fiscal year 2010: $1.05 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: